<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-10308R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007231</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Bioinformatics</subject><subject>Genetics and Genomics/Complex Traits</subject><subject>Genetics and Genomics/Functional Genomics</subject><subject>Genetics and Genomics/Gene Expression</subject><subject>Genetics and Genomics/Gene Function</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Diabetes and Endocrinology/Obesity</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject></subj-group></article-categories><title-group><article-title>Alternative Splicing of <italic>TCF7L2</italic> Gene in Omental and Subcutaneous Adipose Tissue and Risk of Type 2 Diabetes</article-title><alt-title alt-title-type="running-head">TCF7L2 in Human Adipose</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Prokunina-Olsson</surname><given-names>Ludmila</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Lee M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schadt</surname><given-names>Eric E.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>Francis S.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Massachusetts General Hospital (MGH) Weight Center, Boston, Massachusetts, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Pacific Biosciences, Menlo Park, California, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Westermark</surname><given-names>Per</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Uppsala University, Sweden</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>prokuninal@mail.nih.gov</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: LPO LMK EES FSC. Performed the experiments: LPO. Analyzed the data: LPO EES. Contributed reagents/materials/analysis tools: LMK EES. Wrote the paper: LPO EES FSC.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>30</day><month>9</month><year>2009</year></pub-date><volume>4</volume><issue>9</issue><elocation-id>e7231</elocation-id><history><date date-type="received"><day>8</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Single nucleotide polymorphisms (SNPs) rs7903146 and rs12255372 located within <italic>TCF7L2</italic> gene have been identified as the strongest common genetic risk factors for development of type 2 diabetes (T2D). We hypothesized that these genetic variants might increase the risk of T2D through regulation of alternative splicing or expression level of <italic>TCF7L2</italic> in human adipose tissue.</p></sec><sec><title>Methodology/Principal Findings</title><p>Expression of 13 assays detecting alternatively spliced forms of <italic>TCF7L2</italic> was measured by quantitative reverse-transcriptase PCR (qRT-PCR) in paired biopsies of omental and subcutaneous adipose tissue from 159 obese individuals (BMI 54.6&#x0002b;/&#x02212;12.2 kg/m<sup>2</sup>). <italic>TCF7L2</italic> expression in both types of adipose tissue was not associated with SNPs rs7903146 and rs12255372, T2D status and blood levels of glucose or glycosylated hemoglobin (HbA1c). Expression of assays &#x0201c;ex12-13&#x0201d;, &#x0201c;ex12-14&#x0201d; and &#x0201c;ex13-13a&#x0201d; detecting C-terminal alternative exons of <italic>TCF7L2</italic> was higher in subcutaneous compared to omental adipose tissue by 1.46 fold (p&#x0200a;&#x0003d;&#x0200a;6.5&#x000d7;10<sup>&#x02212;15</sup>), 1.41 fold (p&#x0200a;&#x0003d;&#x0200a;1.4&#x000d7;10<sup>&#x02212;9</sup>) and 1.26 fold (p&#x0200a;&#x0003d;&#x0200a;4.7&#x000d7;10<sup>&#x02212;6</sup>) in the control group and by 1.86 fold (p&#x0200a;&#x0003d;&#x0200a;1.7&#x000d7;10<sup>&#x02212;4</sup>), 1.77 fold (p&#x0200a;&#x0003d;&#x0200a;7.3&#x000d7;10<sup>&#x02212;4</sup>) and 1.58 fold (p&#x0200a;&#x0003d;&#x0200a;6.1&#x000d7;10<sup>&#x02212;4</sup>) in the T2D group. A pathway enrichment analysis on transcripts significantly co-expressed with <italic>TCF7L2</italic> in a microarray set combined with individual expression assays, suggested tissue-specific roles of <italic>TCF7L2</italic> splicing forms in regulation of transcription, signal transduction and cell adhesion.</p></sec><sec><title>Conclusions</title><p>Expression of <italic>TCF7L2</italic> alternatively spliced forms may have different functional roles in omental and subcutaneous adipose tissue but is not associated with SNPs rs7903146 and rs12255372 or T2D status.</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Common intronic single nucleotide polymorphisms (SNPs) within the transcription factor 7 - like 2 gene (<italic>TCF7L2</italic>) have been identified as genetic factors that significantly increase risk of type 2 diabetes (T2D) <xref ref-type="bibr" rid="pone.0007231-Grant1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Scott1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Saxena1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Groves1">&#x0005b;4&#x0005d;</xref>. <italic>TCF7L2</italic> belongs to a family of TCF/LEF transcription factors that interact with &#x003b2;-catenin and regulate the WNT pathway <xref ref-type="bibr" rid="pone.0007231-Reya1">&#x0005b;5&#x0005d;</xref>. Activation of the WNT pathway leads to increased cell proliferation due to effects of downstream targets of <italic>TCF7L2</italic> such as <italic>MYC</italic><xref ref-type="bibr" rid="pone.0007231-He1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Muncan1">&#x0005b;7&#x0005d;</xref> and <italic>CCND1</italic> (Cyclin D1) <xref ref-type="bibr" rid="pone.0007231-Tetsu1">&#x0005b;8&#x0005d;</xref>. A complex interplay of activation and repression of the WNT pathway, orchestrated by different protein isoforms of TCF/LEF transcription factors, is required for tissue-specific differentiation of stem cells. For example, differentiation of skin stem cells into either hair follicle or sebum-producing cells is regulated by expression of alternatively spliced forms of the LEF1 transcription factor <xref ref-type="bibr" rid="pone.0007231-Merrill1">&#x0005b;9&#x0005d;</xref>. Similarly, an active WNT pathway is required for myogenesis, while inactivation of the pathway by a dominant-negative form of <italic>TCF7L2</italic> promotes adipogenesis <xref ref-type="bibr" rid="pone.0007231-Ross1">&#x0005b;10&#x0005d;</xref>. Increased adiposity, as measured by body mass index (BMI), is a strong risk factor for development of insulin resistance, T2D and cardiovascular disease <xref ref-type="bibr" rid="pone.0007231-Miranda1">&#x0005b;11&#x0005d;</xref>. Several studies have reported that patients carrying risk alleles of the associated SNPs rs7903146 and rs12255372 of <italic>TCF7L2</italic> have lower BMI compared to carriers of non-risk alleles <xref ref-type="bibr" rid="pone.0007231-Florez1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Cauchi1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Cauchi2">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Cauchi3">&#x0005b;15&#x0005d;</xref>. Potentially, risk alleles of <italic>TCF7L2</italic> might increase risk of T2D even in lean individuals, or affect diabetes and adiposity through independent mechanisms.</p><p>Non-coding genetic variants can affect mRNA expression and splicing <xref ref-type="bibr" rid="pone.0007231-Zhang1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Graham1">&#x0005b;17&#x0005d;</xref>. Several studies attempted to correlate genotypes of T2D-associated variants of <italic>TCF7L2</italic> with mRNA expression of <italic>TCF7L2</italic> in adipose tissue <xref ref-type="bibr" rid="pone.0007231-Cauchi1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Elbein1">&#x0005b;18&#x0005d;</xref> skeletal muscle <xref ref-type="bibr" rid="pone.0007231-Elbein1">&#x0005b;18&#x0005d;</xref>, lymphoblastoid cell lines <xref ref-type="bibr" rid="pone.0007231-Elbein1">&#x0005b;18&#x0005d;</xref> and pancreatic islets <xref ref-type="bibr" rid="pone.0007231-Lyssenko1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Osmark1">&#x0005b;20&#x0005d;</xref>, but no consistent associations have been reported. One study detected a significant decrease in <italic>TCF7L2</italic> expression in obese individuals with T2D compared to obese controls, but this study was based only on six samples <xref ref-type="bibr" rid="pone.0007231-Cauchi1">&#x0005b;13&#x0005d;</xref>. We previously catalogued and evaluated expression of multiple splicing forms of <italic>TCF7L2</italic> in several types of human tissue <xref ref-type="bibr" rid="pone.0007231-ProkuninaOlsson1">&#x0005b;21&#x0005d;</xref>. We observed tentative association between expression of several assays for C-terminal exons of <italic>TCF7L2</italic> and genotypes of SNPs rs7903146 and rs12255372 in pancreatic islets but not in a small set of samples of subcutaneous adipose tissue <xref ref-type="bibr" rid="pone.0007231-ProkuninaOlsson1">&#x0005b;21&#x0005d;</xref>.</p><p>Here, we used 13 assays detecting all known splicing forms of <italic>TCF7L2</italic> to evaluate gene expression in paired biopsies of subcutaneous and omental adipose tissue from 159 obese individuals. We evaluated the association between expression of these assays and genotypes of T2D-associated variants rs7903146 and rs12255372, T2D status, type of adipose tissue, BMI (37.6&#x02013;89.6 kg/m2) and blood levels of glucose and glycosylated hemoglobin (HbA1c). We show that expression of alternatively spliced forms of <italic>TCF7L2</italic> may have different functional roles in omental and subcutaneous adipose tissue but is not associated with SNPs rs7903146 and rs12255372 or T2D status.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Characteristics of the T2D and control groups</title><p>SNPs rs7903146 and rs12255372 are located in introns 3 and 4 of <italic>TCF7L2</italic> gene within the associated linkage disequilibrium (LD) block and 50 kb apart from each other <xref ref-type="bibr" rid="pone.0007231-Grant1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Scott1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Saxena1">&#x0005b;3&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0007231-g001">Fig. 1</xref>). In our set of 159 Caucasian individuals, the frequencies of risk alleles of both SNPs were higher in the T2D group (n&#x0200a;&#x0003d;&#x0200a;16) than in the control group (n&#x0200a;&#x0003d;&#x0200a;143), 0.41 in T2D vs. 0.26 in controls for rs7903146 and 0.38 in T2D vs. 0.25 in controls for rs12255372 (<xref ref-type="table" rid="pone-0007231-t001">Table 1</xref>). Similarly to other European sets <xref ref-type="bibr" rid="pone.0007231-Grant1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Scott1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007231-Saxena1">&#x0005b;3&#x0005d;</xref> and to the European set (CEU) of the HapMap <xref ref-type="bibr" rid="pone.0007231-httphapmap.org1">&#x0005b;22&#x0005d;</xref>, these two SNPs were in high linkage disequilibrium (LD) with each other (D&#x02032;&#x0200a;&#x0003d;&#x0200a;0.88, r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.73). Samples in the T2D and control groups were matched by age, gender and BMI by design but several T2D-related traits were significantly different between these groups: levels of blood glucose, HbA1c and homeostasis model of insulin resistance (Homa-IR) were increased, while the level of HDL cholesterol was decreased in the T2D group (<xref ref-type="table" rid="pone-0007231-t001">Table 1</xref>).</p><fig id="pone-0007231-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007231.g001</object-id><label>Figure 1</label><caption><title>Structure of <italic>TCF7L2</italic> gene and location of expression assays.</title><p>The scheme shows constitutive exons (black rectangles), alternative exons (white rectangles); linkage disequilibrium (LD) block with associated SNPs rs7903146 and rs12255372; protein domains: &#x000df;-catenin-interacting domain, DNA-binding HMG domain and C-terminal Binding Protein (CtBP)-binding domain; expression assays for detection of alternative splicing forms of <italic>TCF7L2</italic> are indicated by connected arrows: assays TSS1, TSS2 and TSS3 target transcripts produced from alternative transcription start sites while other assays target alternatively spliced forms with different combinations of exons, &#x0002a; - expression of assay &#x0201c;ex13-13b&#x0201d; was tested but not detected in adipose tissue.</p></caption><graphic xlink:href="pone.0007231.g001"/></fig><table-wrap id="pone-0007231-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007231.t001</object-id><label>Table 1</label><caption><title>Characteristics of the T2D and control groups.</title></caption><alternatives><graphic id="pone-0007231-t001-1" xlink:href="pone.0007231.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Trait</td><td align="left" rowspan="1" colspan="1">T2D Mean (st.dev)</td><td align="left" rowspan="1" colspan="1">T2D N</td><td align="left" rowspan="1" colspan="1">Control Mean (st.dev)</td><td align="left" rowspan="1" colspan="1">Control N</td><td align="left" rowspan="1" colspan="1">p-value<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">46.53 (12.42)</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">43.78 (10.04)</td><td align="left" rowspan="1" colspan="1">143</td><td align="left" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Male: female ratio</td><td align="left" rowspan="1" colspan="1">52.9&#x02236;47.1</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">47.6&#x02236;52.4</td><td align="left" rowspan="1" colspan="1">143</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, Kg/m2</td><td align="left" rowspan="1" colspan="1">53.62 (15.77)</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">54.77 (11.73)</td><td align="left" rowspan="1" colspan="1">143</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol, mg/dl</td><td align="left" rowspan="1" colspan="1">167.0 (31.48)</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">189.98 (34.70)</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">0.0091</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides, mg/dl</td><td align="left" rowspan="1" colspan="1">205.73 (114.73)</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">168.69 (91.53)</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Leptin, mg/dl</td><td align="left" rowspan="1" colspan="1">43.5 (27.58)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">58.11 (31.19)</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL, mg/dl</td><td align="left" rowspan="1" colspan="1">93.6 (32.8)</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">110.77 (29.42)</td><td align="left" rowspan="1" colspan="1">127</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL, mg/dl</td><td align="left" rowspan="1" colspan="1">37.19 (9.93)</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">46.63(11.65)</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">0.0004</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC, &#x000d7;10<sup>9</sup> cell/l</td><td align="left" rowspan="1" colspan="1">9.16 (2.55)</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">8.41 (2.11)</td><td align="left" rowspan="1" colspan="1">139</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin, mg/dl</td><td align="left" rowspan="1" colspan="1">32.73 (25.53)</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">23.15 (14.16)</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">0.077</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose, mg/dl</td><td align="left" rowspan="1" colspan="1">197.82 (51.19)</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">98.04 (14.25)</td><td align="left" rowspan="1" colspan="1">143</td><td align="left" rowspan="1" colspan="1">2.04&#x000d7;10<sup>&#x02212;37</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Homa-IR</td><td align="left" rowspan="1" colspan="1">316.21 (320.98)</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">102.11 (70.95)</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">5.58&#x000d7;10<sup>&#x02212;7</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1C</td><td align="left" rowspan="1" colspan="1">8.24 (1.30)</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">5.79 (0.59)</td><td align="left" rowspan="1" colspan="1">119</td><td align="left" rowspan="1" colspan="1">1.15&#x000d7;10<sup>&#x02212;23</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Rs 7903146</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">268</td><td align="left" rowspan="1" colspan="1">0.097</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.594</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.738</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.401</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.262</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Rs12255372</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">286</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.625</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.748</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.375</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.252</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>Two-sided T-test or Chi-square test (for allele frequencies) not adjusted for covariates and multiple tests.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Test for association between <italic>TCF7L2</italic> expression and genotypes of rs7903146 and rs12255372, T2D status and blood levels of glucose and HbA1c</title><p>Levels of expression of 13 <italic>TCF7L2</italic> assays in both types of adipose tissue were adjusted for age, sex, BMI and blood levels of glucose and HbA1c. Expression of these assays in each individual tissue and the ratio of subcutaneous: omental expression was similar in the control and T2D groups and in carriers of different genotypes of SNPs rs7903146 and rs1225532 (<xref ref-type="table" rid="pone-0007231-t002">Table 2</xref> and <xref ref-type="table" rid="pone-0007231-t003">3</xref>). Expression of assay &#x0201c;ex13-13b&#x0201d; (<xref ref-type="fig" rid="pone-0007231-g001">Fig. 1</xref>) previously studied in human pancreatic islets <xref ref-type="bibr" rid="pone.0007231-ProkuninaOlsson1">&#x0005b;21&#x0005d;</xref> was tested but not detected in adipose tissue (data not shown). Based on the number of samples and the observed standard deviation in expression of each assay, we had 80&#x00025; power and 95&#x00025; confidence to detect a &#x0003e;1.2-fold difference in expression between groups with risk and non-risk alleles for each SNP and between the T2D and control groups.</p><table-wrap id="pone-0007231-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007231.t002</object-id><label>Table 2</label><caption><title>Expression of <italic>TCF7L2</italic> in omental and subcutaneous adipose tissues: comparison between T2D and control groups, 119 controls, 16 T2D patients.</title></caption><alternatives><graphic id="pone-0007231-t002-2" xlink:href="pone.0007231.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Expression assay</td><td align="left" rowspan="1" colspan="1">Ratio<xref ref-type="table-fn" rid="nt103">a</xref> SA&#x02236;OA p-value<xref ref-type="table-fn" rid="nt104">b</xref></td><td align="left" rowspan="1" colspan="1">OA p-value<xref ref-type="table-fn" rid="nt104">b</xref></td><td align="left" rowspan="1" colspan="1">Effect in T2D<xref ref-type="table-fn" rid="nt105">c</xref></td><td align="left" rowspan="1" colspan="1">SA p-value<xref ref-type="table-fn" rid="nt104">b</xref></td><td align="left" rowspan="1" colspan="1">Effect in T2D<xref ref-type="table-fn" rid="nt105">c</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TSS1</td><td align="left" rowspan="1" colspan="1">0.054</td><td align="left" rowspan="1" colspan="1">0.130</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">0.327</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">TSS2</td><td align="left" rowspan="1" colspan="1">0.069</td><td align="left" rowspan="1" colspan="1">0.074</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">0.057</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">TSS3</td><td align="left" rowspan="1" colspan="1">0.050</td><td align="left" rowspan="1" colspan="1">0.064</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">0.052</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex3a-4</td><td align="left" rowspan="1" colspan="1">0.106</td><td align="left" rowspan="1" colspan="1">0.054</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0.128</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex4-4a</td><td align="left" rowspan="1" colspan="1">0.200</td><td align="left" rowspan="1" colspan="1">0.141</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">0.067</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex7-8</td><td align="left" rowspan="1" colspan="1">0.103</td><td align="left" rowspan="1" colspan="1">0.050</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0.150</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-13</td><td align="left" rowspan="1" colspan="1">0.074</td><td align="left" rowspan="1" colspan="1">0.095</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">0.290</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-13a</td><td align="left" rowspan="1" colspan="1">0.151</td><td align="left" rowspan="1" colspan="1">0.078</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">0.430</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex12-13</td><td align="left" rowspan="1" colspan="1">0.194</td><td align="left" rowspan="1" colspan="1">0.116</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0.098</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex13-13a</td><td align="left" rowspan="1" colspan="1">0.185</td><td align="left" rowspan="1" colspan="1">0.051</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0.277</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex12-14</td><td align="left" rowspan="1" colspan="1">0.054</td><td align="left" rowspan="1" colspan="1">0.055</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0.051</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-14</td><td align="left" rowspan="1" colspan="1">0.409</td><td align="left" rowspan="1" colspan="1">0.755</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0.052</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex13-14</td><td align="left" rowspan="1" colspan="1">0.134</td><td align="left" rowspan="1" colspan="1">0.051</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">0.197</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><p>SA-subcutaneous adipose, OA- omental adipose.</p></fn><fn id="nt103"><label>a</label><p>in paired samples of subcutaneous and omental adipose tissue.</p></fn><fn id="nt104"><label>b</label><p>p-values for univariate analysis, adjusted for age, sex, BMI and blood levels of glucose and HbA1c but not adjusted for multiple tests.</p></fn><fn id="nt105"><label>c</label><p>increase (&#x0002b;) or decrease (&#x02212;) in expression in T2D group compared to controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0007231-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007231.t003</object-id><label>Table 3</label><caption><title>Effect of presence 0, 1 or 2 risk alleles of <italic>TCF7L2</italic> SNPs on expression of <italic>TCF7L2</italic> in paired omental and subcutaneous adipose tissue samples, n&#x0200a;&#x0003d;&#x0200a;134.</title></caption><alternatives><graphic id="pone-0007231-t003-3" xlink:href="pone.0007231.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Expression assay</td><td align="left" rowspan="1" colspan="1">OA p-value<xref ref-type="table-fn" rid="nt108">b</xref> rs7903146</td><td align="left" rowspan="1" colspan="1">SA p-value<xref ref-type="table-fn" rid="nt108">b</xref> rs7903146</td><td align="left" rowspan="1" colspan="1">Ratio<xref ref-type="table-fn" rid="nt107">a</xref> p-value<xref ref-type="table-fn" rid="nt108">b</xref> rs7903146</td><td align="left" rowspan="1" colspan="1">OA p-value<xref ref-type="table-fn" rid="nt108">b</xref> rs12255372</td><td align="left" rowspan="1" colspan="1">SA p-value<xref ref-type="table-fn" rid="nt108">b</xref> rs12255372</td><td align="left" rowspan="1" colspan="1">Ratio<xref ref-type="table-fn" rid="nt107">a</xref> p-value<xref ref-type="table-fn" rid="nt108">b</xref> rs12255372</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TSS1</td><td align="left" rowspan="1" colspan="1">0.368</td><td align="left" rowspan="1" colspan="1">0.168</td><td align="left" rowspan="1" colspan="1">0.341</td><td align="left" rowspan="1" colspan="1">0.288</td><td align="left" rowspan="1" colspan="1">0.306</td><td align="left" rowspan="1" colspan="1">0.186</td></tr><tr><td align="left" rowspan="1" colspan="1">TSS2</td><td align="left" rowspan="1" colspan="1">0.176</td><td align="left" rowspan="1" colspan="1">0.157</td><td align="left" rowspan="1" colspan="1">0.216</td><td align="left" rowspan="1" colspan="1">0.277</td><td align="left" rowspan="1" colspan="1">0.162</td><td align="left" rowspan="1" colspan="1">0.128</td></tr><tr><td align="left" rowspan="1" colspan="1">TSS3</td><td align="left" rowspan="1" colspan="1">0.166</td><td align="left" rowspan="1" colspan="1">0.170</td><td align="left" rowspan="1" colspan="1">0.185</td><td align="left" rowspan="1" colspan="1">0.143</td><td align="left" rowspan="1" colspan="1">0.533</td><td align="left" rowspan="1" colspan="1">0.358</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex3a-4</td><td align="left" rowspan="1" colspan="1">0.075</td><td align="left" rowspan="1" colspan="1">0.081</td><td align="left" rowspan="1" colspan="1">0.079</td><td align="left" rowspan="1" colspan="1">0.072</td><td align="left" rowspan="1" colspan="1">0.114</td><td align="left" rowspan="1" colspan="1">0.064</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex4-4a</td><td align="left" rowspan="1" colspan="1">0.203</td><td align="left" rowspan="1" colspan="1">0.069</td><td align="left" rowspan="1" colspan="1">0.204</td><td align="left" rowspan="1" colspan="1">0.064</td><td align="left" rowspan="1" colspan="1">0.064</td><td align="left" rowspan="1" colspan="1">0.109</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex7-8</td><td align="left" rowspan="1" colspan="1">0.188</td><td align="left" rowspan="1" colspan="1">0.126</td><td align="left" rowspan="1" colspan="1">0.254</td><td align="left" rowspan="1" colspan="1">0.218</td><td align="left" rowspan="1" colspan="1">0.051</td><td align="left" rowspan="1" colspan="1">0.128</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-13</td><td align="left" rowspan="1" colspan="1">0.269</td><td align="left" rowspan="1" colspan="1">0.070</td><td align="left" rowspan="1" colspan="1">0.285</td><td align="left" rowspan="1" colspan="1">0.221</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">0.147</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-13a</td><td align="left" rowspan="1" colspan="1">0.122</td><td align="left" rowspan="1" colspan="1">0.331</td><td align="left" rowspan="1" colspan="1">0.485</td><td align="left" rowspan="1" colspan="1">0.217</td><td align="left" rowspan="1" colspan="1">0.274</td><td align="left" rowspan="1" colspan="1">0.583</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex12-13</td><td align="left" rowspan="1" colspan="1">0.348</td><td align="left" rowspan="1" colspan="1">0.050</td><td align="left" rowspan="1" colspan="1">0.255</td><td align="left" rowspan="1" colspan="1">0.303</td><td align="left" rowspan="1" colspan="1">0.071</td><td align="left" rowspan="1" colspan="1">0.148</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex13-13a</td><td align="left" rowspan="1" colspan="1">0.256</td><td align="left" rowspan="1" colspan="1">0.088</td><td align="left" rowspan="1" colspan="1">0.252</td><td align="left" rowspan="1" colspan="1">0.315</td><td align="left" rowspan="1" colspan="1">0.097</td><td align="left" rowspan="1" colspan="1">0.261</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex12-14</td><td align="left" rowspan="1" colspan="1">0.137</td><td align="left" rowspan="1" colspan="1">0.055</td><td align="left" rowspan="1" colspan="1">0.111</td><td align="left" rowspan="1" colspan="1">0.174</td><td align="left" rowspan="1" colspan="1">0.133</td><td align="left" rowspan="1" colspan="1">0.056</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-14</td><td align="left" rowspan="1" colspan="1">0.410</td><td align="left" rowspan="1" colspan="1">0.071</td><td align="left" rowspan="1" colspan="1">0.217</td><td align="left" rowspan="1" colspan="1">0.421</td><td align="left" rowspan="1" colspan="1">0.114</td><td align="left" rowspan="1" colspan="1">0.116</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex13-14</td><td align="left" rowspan="1" colspan="1">0.187</td><td align="left" rowspan="1" colspan="1">0.085</td><td align="left" rowspan="1" colspan="1">0.135</td><td align="left" rowspan="1" colspan="1">0.178</td><td align="left" rowspan="1" colspan="1">0.102</td><td align="left" rowspan="1" colspan="1">0.066</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><p>SA-subcutaneous adipose, OA- omental adipose.</p></fn><fn id="nt107"><label>a</label><p>ratio subcutaneous&#x02236;omental expression in paired samples.</p></fn><fn id="nt108"><label>b</label><p>p-value for linear regression model with 0, 1 or 2 risk alleles of <italic>TCF7L2</italic> SNPs adjusted for age, sex, BMI, T2D status and blood levels of glucose and HbA1c but not adjusted for multiple tests.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Difference in <italic>TCF7L2</italic> expression between omental and subcutaneous adipose tissues</title><p>Expression of several assays was higher in subcutaneous compared to omental adipose tissue both in the control and T2D groups: 1.46 and 1.86-fold for assay &#x0201c;ex12-13&#x0201d;, 1.41 and 1.77-fold for assay &#x0201c;ex12-14&#x0201d; and 1.26 and 1.58-fold for assay &#x0201c;ex13-13a&#x0201d; (<xref ref-type="table" rid="pone-0007231-t004">Table 4</xref>). Only expression of alternative exon 3a (assay &#x0201c;ex3a-4&#x0201d;) was decreased in subcutaneous compared to adipose tissue (0.81 fold) in the control group, but not in the T2D group (0.91 fold) (<xref ref-type="table" rid="pone-0007231-t004">Table 4</xref>). The results for assays &#x0201c;ex12-13&#x0201d;, &#x0201c;13-13a&#x0201d; and &#x0201c;12-14&#x0201d; will remain significant even after adjustment for multiple tests. Different ways of normalization of <italic>TCF7L2</italic> expression (by expression levels of endogenous controls <italic>B2M</italic>, <italic>GAPDH</italic> or both genes together) did not significantly affect the conclusions (data not shown). The assays &#x0201c;ex12-13&#x0201d;, &#x0201c;13-13a&#x0201d; and &#x0201c;12-14&#x0201d; detect two distinct splicing forms that include alternative exon 12 (<xref ref-type="fig" rid="pone-0007231-g002">Figure 2</xref>). The first form (GenBank FJ010174) includes C-terminal exons 11-12-13-13a and encodes a protein with a short reading frame terminated by an alternative stop codon within exon 13a. The second form (GenBank FJ010170) includes exons 11-12-14 and encodes a protein with a medium reading frame terminated by an alternative stop codon in the beginning of exon 14 (<xref ref-type="fig" rid="pone-0007231-g002">Fig. 2</xref>).</p><fig id="pone-0007231-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007231.g002</object-id><label>Figure 2</label><caption><title>Alternative splicing forms of <italic>TCF7L2</italic> with increased expression in subcutaneous compared to omental adipose.</title><p>A. Constitutive exons 11 and 14 are marked as black rectangles, alternative exons 12, 13, 13a, 13b are marked as white rectangles, black triangles above exons indicate location of alternative stop codons that define protein reading frames: short (S), medium (M) or long (L); B. Alternative splicing form with exons 11-12-13-13a (GenBank FJ010174) has an alternative stop codon within exon 13a and encodes a protein with short reading frame; C. Alternative splicing form with exons 11-12-14 (GenBank FJ010170) has an alternative stop codon in the beginning of exon 14 and encodes a protein with medium reading frame. Positions of expression assays &#x0201c;ex12-13&#x0201d;, &#x0201c;ex13-13a&#x0201d; and &#x0201c;12-14&#x0201d; used in this study are indicated above corresponding exons. Assays &#x0201c;ex12-13&#x0201d;, &#x0201c;ex13-13a&#x0201d; and &#x0201c;12-14&#x0201d; detect all splicing forms of <italic>TCF7L2</italic> that include alternative exon 12.</p></caption><graphic xlink:href="pone.0007231.g002"/></fig><table-wrap id="pone-0007231-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007231.t004</object-id><label>Table 4</label><caption><title>Expression of <italic>TCF7L2</italic> in omental and subcutaneous adipose tissue in controls (n&#x0200a;&#x0003d;&#x0200a;143) and T2D (n&#x0200a;&#x0003d;&#x0200a;16) groups.</title></caption><alternatives><graphic id="pone-0007231-t004-4" xlink:href="pone.0007231.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Expression assay</td><td align="left" rowspan="1" colspan="1">Controls, OA, reference</td><td align="left" rowspan="1" colspan="1">Controls, SA, fold to reference</td><td align="left" rowspan="1" colspan="1">controls p-value<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">T2D OA, reference</td><td align="left" rowspan="1" colspan="1">T2D SA, fold to reference</td><td align="left" rowspan="1" colspan="1">T2D p-value<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TSS1</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">TSS2</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.04</td><td align="left" rowspan="1" colspan="1">0.539</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">0.283</td></tr><tr><td align="left" rowspan="1" colspan="1">TSS3</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.066</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">0.353</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex3a-4</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.81</td><td align="left" rowspan="1" colspan="1">2.6&#x000d7;10<sup>&#x02212;4</sup></td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.516</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex4-4a</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.07</td><td align="left" rowspan="1" colspan="1">0.231</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.21</td><td align="left" rowspan="1" colspan="1">0.185</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex7-8</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">0.047</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.24</td><td align="left" rowspan="1" colspan="1">0.056</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-13</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.09</td><td align="left" rowspan="1" colspan="1">0.053</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">0.213</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-13a</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.09</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">0.0013</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex12-13</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.46</td><td align="left" rowspan="1" colspan="1">6.45&#x000d7;10<sup>&#x02212;15</sup></td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.86</td><td align="left" rowspan="1" colspan="1">1.7&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Ex13-13a</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.26</td><td align="left" rowspan="1" colspan="1">4.7&#x000d7;10<sup>&#x02212;6</sup></td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.58</td><td align="left" rowspan="1" colspan="1">6.1&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Ex12-14</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.41</td><td align="left" rowspan="1" colspan="1">1.4&#x000d7;10<sup>&#x02212;9</sup></td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.77</td><td align="left" rowspan="1" colspan="1">7.3&#x000d7;10<sup>&#x02212;4</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Ex11-14</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">2.7&#x000d7;10<sup>&#x02212;4</sup></td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.49</td><td align="left" rowspan="1" colspan="1">0.0120</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex13-14</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">0.0062</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.32</td><td align="left" rowspan="1" colspan="1">0.052</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><p>SA-subcutaneous adipose, OA- omental adipose.</p></fn><fn id="nt110"><label>&#x0002a;</label><p>- Two-sided T-test, p-values are not adjusted for multiple tests; expression in omental adipose is taken as 1.0 for each assay.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2d"><title>Pathway enrichment analysis of <italic>TCF7L2</italic> expression</title><p>To better understand the function of <italic>TCF7L2</italic> in human adipose tissue we searched for transcripts that positively or negatively correlated with expression of <italic>TCF7L2</italic>. We combined global expression data measured by microarrays <xref ref-type="bibr" rid="pone.0007231-Zhong1">&#x0005b;23&#x0005d;</xref> with data for individual expression assays &#x0201c;ex7-8&#x0201d;, &#x0201c;ex3a-4&#x0201d;, &#x0201c;ex12-13&#x0201d; and &#x0201c;ex13-13a&#x0201d;, generated in the same set of 159 samples of omental and subcutaneous adipose tissue. On the microarrays, <italic>TCF7L2</italic> was represented by 2 probes located within the 3&#x02032; untranslated region (UTR) of RefSeq transcript NM_030756. The microarray probes and the assay &#x0201c;ex7-8&#x0201d; detect a mix of all splicing forms of <italic>TCF7L2</italic>, while the assays &#x0201c;ex12-13&#x0201d;, &#x0201c;ex13-13a&#x0201d; and &#x0201c;ex3a-4&#x0201d; detect distinct splicing forms that showed difference in expression between the two types of adipose tissue. There was a significant correlation between the microarray and TaqMan expression data in omental adipose tissue: r2&#x0200a;&#x0003d;&#x0200a;0.51 for assay &#x0201c;ex7-8&#x0201d;, r2&#x0200a;&#x0003d;&#x0200a;0.49 for assay &#x0201c;ex13-13a&#x0201d;, r2&#x0200a;&#x0003d;&#x0200a;0.42 for assay &#x0201c;ex12-13&#x0201d; and r2&#x0200a;&#x0003d;&#x0200a;0.31 for &#x0201c;ex3a-4&#x0201d; but in subcutaneous adipose tissue the correlation for the same assays was not significant (r2&#x0003c;0.25). Using the joint expression set (microarrays and TaqMan data), we identified sets of transcripts that correlated with expression of these assays at a cutoff of r2&#x0003e;&#x0002b;/&#x02212;0.25, corresponding to False Discovery Rate (FDR) p&#x0003c;0.0015, and analyzed each set of transcripts for enrichment of Gene Ontology categories (GO). In omental adipose tissue <italic>TCF7L2</italic> expression positively correlated with activation of transcription through KRAB box Zn finger transcription factors but negatively correlated with protein biosynthesis, signal transduction, oxidative phosphorylation and electron transport (<xref ref-type="table" rid="pone-0007231-t005">Table 5</xref>). In subcutaneous adipose tissue the strongest positive correlation was between expression of assay &#x0201c;ex13-13a&#x0201d; and the cadherin signaling pathway and cell adhesion, while negative correlation was detected with protein biosynthesis and receptor function (<xref ref-type="table" rid="pone-0007231-t005">Table 5</xref>). Full list of transcripts with positive and negative correlations with <italic>TCF7L2</italic> assays &#x0201c;ex12-13&#x0201d; and &#x0201c;ex13-13a&#x0201d; are presented in <xref ref-type="supplementary-material" rid="pone.0007231.s002">Tables S2</xref>, <xref ref-type="supplementary-material" rid="pone.0007231.s003">S3</xref>, <xref ref-type="supplementary-material" rid="pone.0007231.s004">S4</xref>, <xref ref-type="supplementary-material" rid="pone.0007231.s005">S5</xref>.</p><table-wrap id="pone-0007231-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007231.t005</object-id><label>Table 5</label><caption><title>Panther Classification System analysis of <italic>TCF7L2</italic> expression in adipose tissue.</title></caption><alternatives><graphic id="pone-0007231-t005-5" xlink:href="pone.0007231.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene Ontology category</td><td align="left" rowspan="1" colspan="1">Tissue, correlation<xref ref-type="table-fn" rid="nt112">a</xref></td><td align="left" rowspan="1" colspan="1"><italic>TCF7L2</italic> assay</td><td align="left" rowspan="1" colspan="1">array, n<xref ref-type="table-fn" rid="nt113">b</xref></td><td align="left" rowspan="1" colspan="1">observed, n<xref ref-type="table-fn" rid="nt114">c</xref></td><td align="left" rowspan="1" colspan="1">expected, n<xref ref-type="table-fn" rid="nt115">d</xref></td><td align="left" rowspan="1" colspan="1">direction<xref ref-type="table-fn" rid="nt116">e</xref></td><td align="left" rowspan="1" colspan="1">p-value<xref ref-type="table-fn" rid="nt117">f</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ribosomal protein</td><td align="left" rowspan="1" colspan="1">OA, N</td><td align="left" rowspan="1" colspan="1">ex3a-4</td><td align="left" rowspan="1" colspan="1">473</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">5.15</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">3.23E-13</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein biosynthesis</td><td align="left" rowspan="1" colspan="1">OA, N</td><td align="left" rowspan="1" colspan="1">ex3a-4</td><td align="left" rowspan="1" colspan="1">591</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">6.43</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">9.73E-11</td></tr><tr><td align="left" rowspan="1" colspan="1">Oxidative phosphorylation</td><td align="left" rowspan="1" colspan="1">OA, N</td><td align="left" rowspan="1" colspan="1">ex3a-4</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">.92</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">2.62E-09</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal transduction</td><td align="left" rowspan="1" colspan="1">OA, N</td><td align="left" rowspan="1" colspan="1">ex3a-4</td><td align="left" rowspan="1" colspan="1">3412</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">37.12</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">6.33E-07</td></tr><tr><td align="left" rowspan="1" colspan="1">Electron transport</td><td align="left" rowspan="1" colspan="1">OA, N</td><td align="left" rowspan="1" colspan="1">ex3a-4</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">2.76</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">5.44E-06</td></tr><tr><td align="left" rowspan="1" colspan="1">Defense/immunity protein</td><td align="left" rowspan="1" colspan="1">OA, N</td><td align="left" rowspan="1" colspan="1">ex12-13</td><td align="left" rowspan="1" colspan="1">401</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">3.32</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">9.87E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">Nucleic acid metabolism</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex13-13a</td><td align="left" rowspan="1" colspan="1">3038</td><td align="left" rowspan="1" colspan="1">105</td><td align="left" rowspan="1" colspan="1">70.58</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">5.10E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">Transcription factor</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex13-13a</td><td align="left" rowspan="1" colspan="1">1796</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">41.73</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">2.41E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">KRAB box transcription factor</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex7-8</td><td align="left" rowspan="1" colspan="1">431</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">22.04</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">8.01E-12</td></tr><tr><td align="left" rowspan="1" colspan="1">Nucleic acid metabolism</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex7-8</td><td align="left" rowspan="1" colspan="1">3038</td><td align="left" rowspan="1" colspan="1">233</td><td align="left" rowspan="1" colspan="1">155.37</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">3.51E-09</td></tr><tr><td align="left" rowspan="1" colspan="1">Zinc finger transcription factor</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex7-8</td><td align="left" rowspan="1" colspan="1">727</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">37.18</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">4.92E-08</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell surface receptor mediated signal transduction</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex7-8</td><td align="left" rowspan="1" colspan="1">1596</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">81.62</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">5.52E-07</td></tr><tr><td align="left" rowspan="1" colspan="1">Receptor</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex7-8</td><td align="left" rowspan="1" colspan="1">1476</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">75.49</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">3.51E-07</td></tr><tr><td align="left" rowspan="1" colspan="1">G-protein mediated signaling</td><td align="left" rowspan="1" colspan="1">OA, P</td><td align="left" rowspan="1" colspan="1">ex7-8</td><td align="left" rowspan="1" colspan="1">786</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">40.20</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">2.42E-05</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribosomal protein</td><td align="left" rowspan="1" colspan="1">SA, N</td><td align="left" rowspan="1" colspan="1">ex3a-4</td><td align="left" rowspan="1" colspan="1">473</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">19.44</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">5.48E-05</td></tr><tr><td align="left" rowspan="1" colspan="1">Receptor</td><td align="left" rowspan="1" colspan="1">SA, N</td><td align="left" rowspan="1" colspan="1">ex12-13</td><td align="left" rowspan="1" colspan="1">444</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">18.20</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">2.81E-05</td></tr><tr><td align="left" rowspan="1" colspan="1">Cadherin</td><td align="left" rowspan="1" colspan="1">SA, P</td><td align="left" rowspan="1" colspan="1">ex13-13a</td><td align="left" rowspan="1" colspan="1">156</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">2.23</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">4.17E-12</td></tr><tr><td align="left" rowspan="1" colspan="1">Cadherin signaling pathway</td><td align="left" rowspan="1" colspan="1">SA, P</td><td align="left" rowspan="1" colspan="1">ex13-13a</td><td align="left" rowspan="1" colspan="1">214</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">3.05</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">1.57E-09</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT signaling pathway</td><td align="left" rowspan="1" colspan="1">SA, P</td><td align="left" rowspan="1" colspan="1">ex13-13a</td><td align="left" rowspan="1" colspan="1">400</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">5.71</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">1.96E-07</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell adhesion-mediated signaling</td><td align="left" rowspan="1" colspan="1">SA, P</td><td align="left" rowspan="1" colspan="1">ex13-13a</td><td align="left" rowspan="1" colspan="1">433</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">6.18</td><td align="left" rowspan="1" colspan="1">&#x0002b;</td><td align="left" rowspan="1" colspan="1">4.88E-06</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt111"><p>OA &#x02013; omental adipose; SA &#x02013; subcutaneous adipose; P-positive correlation with <italic>TCF7L2</italic>, N-negative correlation with <italic>TCF7L2</italic>.</p></fn><fn id="nt112"><label>a</label><p>transcripts with positive or negative correlation (r2&#x0003e;&#x0002b;/&#x02212;0.25, p&#x0003c;0.0015) with expression of <italic>TCF7L2</italic> assays.</p></fn><fn id="nt113"><label>b</label><p>number of transcripts in each GO category among 20,316 annotated transcripts on the array.</p></fn><fn id="nt114"><label>c</label><p>number of transcripts with significant correlation with <italic>TCF7L2</italic> expression in each GO category.</p></fn><fn id="nt115"><label>d</label><p>expected number of transcripts in each GO category based on the frequencies on the array.</p></fn><fn id="nt116"><label>e</label><p>direction (enrichment or deficit) in each GO category.</p></fn><fn id="nt117"><label>f</label><p>p-value for differences between observed and expected number of transcripts in each GO category Bonferroni-adjusted for number of GO categories.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>Discussion</title><p>Our study provides a detailed analysis of expression of multiple <italic>TCF7L2</italic> splicing forms in paired biopsies of omental and subcutaneous adipose tissue from a large set of obese individuals. The first goal of this study was to evaluate the association between the expression of <italic>TCF7L2</italic> splicing forms and T2D-associated SNPs rs7903146 and rs12255372, T2D status or blood levels of glucose or HbA1c. Despite 80&#x00025; of power to detect &#x0003e;1.2 fold differences in expression between different groups, we did not observe any significant association between these factors. Our results are similar to a recently published data on 235 samples of subcutaneous adipose tissue where expression of <italic>TCF7L2</italic> (measured by one assay corresponding to our &#x0201c;ex7-8&#x0201d; assay) was not affected by T2D status, sex, and genotypes of rs7903146 <xref ref-type="bibr" rid="pone.0007231-Wegner1">&#x0005b;24&#x0005d;</xref>.</p><p>The second goal of this study was to compare the expression of <italic>TCF7L2</italic> splicing forms in two types of adipose tissue. We observed that expression of assays &#x0201c;ex12-13&#x0201d;, &#x0201c;ex12-14&#x0201d; and &#x0201c;ex13-13a&#x0201d; was higher in subcutaneous compared to omental tissue and this difference could not be explained by genotypes of the T2D-associated SNPs, sex, BMI and blood levels of glucose and HbA1c. These findings were similar to the results of a study that did not detect association between expression of assay &#x0201c;ex9-10&#x0201d; of <italic>TCF7L2</italic> and genotypes of rs7903146, rs12255372, age, sex and BMI in paired biopsies of adipose tissue from 49 individuals <xref ref-type="bibr" rid="pone.0007231-Kovacs1">&#x0005b;25&#x0005d;</xref>. However, the expression of this assay was 4.8-fold higher in subcutaneous compared to omental tissue in controls and 6-fold higher in the T2D group <xref ref-type="bibr" rid="pone.0007231-Kovacs1">&#x0005b;25&#x0005d;</xref>. The effects observed in our study were weaker, 1.46-fold in the control group and 1.86-fold in the T2D group and the effect was not detectable for assay &#x0201c;ex7-8&#x0201d; that measures the same splicing forms as assay &#x0201c;ex9-10&#x0201d;. This could potentially be attributed to the difference in sample size (159 samples in our study and 49 samples in Kovacs et al.), use of different custom-designed expression assays and reference genes (one reference gene at Kovacs et al. and two reference genes in our study). Additionally, individuals in our study were more obese (BMI 54.6&#x0002b;/&#x02212;12.2) compared to less obese individuals in Kovacs et al (BMI 29.7&#x0002b;/&#x02212;0.8 kg/m2) <xref ref-type="bibr" rid="pone.0007231-Kovacs1">&#x0005b;25&#x0005d;</xref>.</p><p><italic>TCF7L2</italic> is a ubiquitously expressed transcription factor that mediates signals of the WNT pathway. The function of <italic>TCF7L2</italic> and, particularly, in different types of adipose tissue is not clear. A pathway enrichment analysis on transcripts significantly coexpressed with <italic>TCF7L2</italic> showed that the main role of <italic>TCF7L2</italic> in omental adipose tissue is associated with activation of transcription and inhibition of protein biosynthesis and signal transduction. In contrast, in subcutaneous adipose tissue we did not observe any evidence for correlation with activation of transcription, but with increased cell adhesion through cadherin protein family (for assay &#x0201c;ex13-13a&#x0201d;). Adipose consists of several types of cells such as adipocytes, endothelial cells, macrophages that can differently express <italic>TCF7L2</italic>. For example, assays &#x0201c;ex12-13&#x0201d; and &#x0201c;13-13a&#x0201d; specifically detect a unique splicing form that includes exons 12-13-13a, expressed in multiple tissues and is the major <italic>TCF7L2</italic> splicing form in peripheral blood monocytes (<xref ref-type="bibr" rid="pone.0007231-ProkuninaOlsson1">&#x0005b;21&#x0005d;</xref>, GenBank FJ010174, <xref ref-type="fig" rid="pone-0007231-g002">Figure 2</xref>). Adhesion of monocytes to endothelial lining of capillaries, infiltration into adipose tissue and differentiation into macrophages contributes to low-grade chronic inflammation in adipose tissue and development of insulin resistance <xref ref-type="bibr" rid="pone.0007231-Osmark1">&#x0005b;20&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007231-httphapmap.org1">&#x0005b;22&#x0005d;</xref>. Therefore, increased expression of assays &#x0201c;ex12-13&#x0201d; and &#x0201c;ex13-13a&#x0201d; in subcutaneous adipose tissue and co-expression with genes involved in cell adhesion might indicate increased monocytes influx into subcutaneous adipose tissue or other functional differences between these two tissue types. All assays of <italic>TCF7L2</italic> with significantly increased expression in subcutaneous compared to omental adipose (&#x0201c;ex12-13&#x0201d;, &#x0201c;ex13-13a&#x0201d; and &#x0201c;ex12-14&#x0201d;) detect splicing forms that encode truncated TCF7L2 protein with short or medium reading frames and include an alternative exon 12 (<xref ref-type="fig" rid="pone-0007231-g002">Figure 2</xref>). The truncated protein isoforms of TCF7L2 lack binding sites for the CTBP protein are not post-translationally regulated and may provide alternative regulation of the WNT pathway <xref ref-type="bibr" rid="pone.0007231-Fang1">&#x0005b;26&#x0005d;</xref>.</p><p>In conclusion, we did not observe association between expression of <italic>TCF7L2</italic> splicing forms, T2D status and genotypes of T2D-associated SNPs rs7903146 and rs12255372. Differential expression of <italic>TCF7L2</italic> splicing forms with alternative exon 12 encoding for truncated protein isoforms of TCF7L2 in omental and subcutaneous adipose tissues deserves future studies.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Ethics Statement</title><p>The study on anonymized samples was approved by the Internal Review Board (IRB) of Massachusetts General Hospital, protocol #2001-P-001942/22 and exempted from IRB approval at the NHGRI/NIH.</p></sec><sec id="s4b"><title>Tissue samples</title><p>Paired samples of omental and subcutaneous adipose tissue were obtained from bariatric patients that underwent weight-reduction surgery and signed informed consent forms <xref ref-type="bibr" rid="pone.0007231-Zhong1">&#x0005b;23&#x0005d;</xref>. Following traits were available for all or subsets of samples: age, gender, BMI, white blood cells counts (WBC), fasting levels of glucose, insulin, total cholesterol, HDL and LDL cholesterol, triglycerides, homeostasis model of insulin resistance (Homa-IR) and glycosylated hemoglobin (HbA1c). The T2D status was assigned to individuals with fasting blood glucose higher than 140 mg/dl (7.8 mmol/L). Total RNA from flash-frozen adipose samples was extracted using Trizol reagent (Invitrogen) and DNA was isolated from liver samples of the same patients with DNeasy kit (Qiagen).</p></sec><sec id="s4c"><title>Genotyping</title><p>Genotyping was performed with pre-developed TaqMan allelic discrimination assays for rs7903146 and rs12255372 (Applied Biosystems). The genotyping success was above 99&#x00025; and only samples genotyped for both markers were used.</p></sec><sec id="s4d"><title>Quantitative reverse-transcriptase PCR (qRT-PCR) expression studies</title><p>cDNA was prepared from total RNA of selected samples of omental and subcutaneous adipose tissue used for the microarray expression studies <xref ref-type="bibr" rid="pone.0007231-Zhong1">&#x0005b;23&#x0005d;</xref>. For each sample, 100 ng of total RNA was convereted to cDNA with SuperScript III reverse transcriptase and random hexamers (Invitrogen). Expression assays for <italic>TCF7L2</italic> were custom designed for each splicing form (<xref ref-type="bibr" rid="pone.0007231-ProkuninaOlsson1">&#x0005b;21&#x0005d;</xref> and <xref ref-type="supplementary-material" rid="pone.0007231.s001">Table S1</xref>). Primers for SYBR Green assays were purchased from Integrated DNA Technologies and TaqMan assays were manufactured on demand by Applied Biosystems. qRT-PCR was performed in a 10 ul reaction volume in 384 well plates with Power SYBR Green master mix (Applied Biosystems) or Expression Master Mix for TaqMan assays (Applied Biosystems) on the Sequence Detection System 7900 (Applied Biosystems). Each expression assay was run in technical duplicates and the average values for each sample were normalized to a geometric mean of mRNA levels of reference genes beta 2 microglobulin (B2M, assay Hs00187842_m1, Applied Biosystems) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, assay 4333764F, Applied Biosystems) run in separate reactions from the same cDNA preparations.</p></sec><sec id="s4e"><title>Statistical analyses</title><p>qRT-PCR expression was measured in Ct values (PCR cycle at which expression was detected). For each sample and assay, the average of technical replicates was first normalized to a geometric mean values of reference genes, B2M and GAPDH according to the formula: Ct(geometric)&#x0200a;&#x0003d;&#x0200a;(Ct(B2M)&#x0002b;Ct(GAPDH))/2. Relative expression of each assay was calculated as: dCt&#x0200a;&#x0003d;&#x0200a;Ct(geometric)&#x02212;Ct(assay). For each assay, the dCt values were first tested for normality of distribution. The association between expression of <italic>TCF7L2</italic> assays and the counts of risk alleles (0, 1, 2) of the T2D-associated SNPs rs7903145 and rs12255372 was tested with univariate linear regression model with adjustment for covariates (age, sex, and log-transformed values of BMI and blood levels of glucose and HbA1c). The analyses were performed with SPSS 16.0 (SPSS Inc.). Microarray expression was analyzed with R statistical programming package. Power analysis was performed with StatMate 2.0 (GraphPad) and was based on standard deviations in expression of each of assays, number of samples with 0 or 1 and 2 risk alleles at each SNP and 80&#x00025; power to detect the difference with 5&#x00025; of type I error.</p></sec><sec id="s4f"><title>Joint analysis of the microarray and TaqMan data, pathway enrichment analysis</title><p>The microarray data for 159 paired samples of omental and subcutaneous adipose tissue was a part of a previously described study <xref ref-type="bibr" rid="pone.0007231-Zhong1">&#x0005b;23&#x0005d;</xref>. The microarray data was available to all authors of the article and is available upon request. Each of the RNA samples was profiled with custom-designed microarrays that included 39,280 oligonucleotide probes representing 34,266 known and predicted genes (Agilent Technologies, Palo Alto, CA). We used assays &#x0201c;ex3a-4&#x0201d;, &#x0201c;ex7-8&#x0201d;, ex&#x0201d;12-13&#x0201d; and &#x0201c;ex13-13a&#x0201d; of <italic>TCF7L2</italic> for joint analysis of expression. Expression of <italic>B2M</italic> and <italic>GAPDH</italic> was used as an endogenous control for TaqMan <italic>TCF7L2</italic> expression. However, when we combined the TaqMan and microarray data, we observed that the sets of transcripts that correlated with <italic>TCF7L2</italic> expression significantly overlapped with the set of transcripts that correlated with <italic>GAPDH</italic> and <italic>B2M</italic> expression. To remove this biologically relevant variation component from the <italic>GAPDH</italic> and <italic>B2M</italic> expression, we identified a set of transcripts that correlated with the geometric mean of <italic>B2M</italic> and <italic>GAPDH</italic> expression at a 5&#x00025; FDR (false-discovery rate). We then performed Principal Component Analysis on this set of transcripts to identify those factors (eigenvectors) that explained greater than 90&#x00025; of the variation in the <italic>GAPDH/B2M</italic> geometric mean and adjusted the <italic>GAPDH/B2M</italic> expression by each of these eigenvectors. The adjusted <italic>B2M/GAPDH</italic> expression was then used to normalize <italic>TCF7L2</italic> expression using standard linear regression methods. For co-expression analysis, the normalized expression values for all transcripts were adjusted for age and sex and the residuals were computed using the rlm function from the R statistical package (M-estimation with Tukey's bisquare weights). The Spearman correlation coefficients for expression of <italic>TCF7L2</italic> and all other transcripts were calculated. The FDR for these correlations was calculated by performing 1000 permutations of sample IDs while preserving the correlation structure among the gene expression values. The threshold for Spearman coefficient was set up at r&#x0200a;&#x0003d;&#x0200a;&#x0002b;/&#x02212;0.25, corresponding to FDR&#x0003c;1&#x00025; (p-value&#x0003c;0.0005). The pathway enrichment analysis on sets of transcripts with significant correlations was performed using the Panther Classification System <xref ref-type="bibr" rid="pone.0007231-Thomas1">&#x0005b;27&#x0005d;</xref>. For each GO category, we compared expected and observed frequencies between a set of 20,316 annotated transcripts presented on the array and the sets of transcripts significantly correlated with <italic>TCF7L2</italic> expression. The p-value for significance of enrichment in each group was adjusted for the number of GO categories using Bonferroni method implemented in the Panther analysis <xref ref-type="bibr" rid="pone.0007231-Thomas1">&#x0005b;27&#x0005d;</xref>.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0007231.s001"><label>Table S1</label><caption><p>Primers and probes for expression assays.</p><p>(0.04 MB RTF)</p></caption><media xlink:href="pone.0007231.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007231.s002"><label>Table S2</label><caption><p>List of significant correlations between TCF7L2 assay.</p><p>(0.05 MB XLS)</p></caption><media xlink:href="pone.0007231.s002.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007231.s003"><label>Table S3</label><caption><p>List of significant correlations between TCF7L2 assay.</p><p>(0.27 MB XLS)</p></caption><media xlink:href="pone.0007231.s003.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007231.s004"><label>Table S4</label><caption><p>List of significant correlations between TCF7L2 assay.</p><p>(0.17 MB XLS)</p></caption><media xlink:href="pone.0007231.s004.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007231.s005"><label>Table S5</label><caption><p>List of significant correlations between TCF7L2 assay.</p><p>(0.11 MB XLS)</p></caption><media xlink:href="pone.0007231.s005.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We are thankful to all patients participated in this study, Victor Castro at MGH for assistance in sample collection, Christine Suver and the Rosetta Gene Expression Laboratory for sample preparation.</p></ack><ref-list><title>References</title><ref id="pone.0007231-Grant1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>SF</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Reynisdottir</surname><given-names>I</given-names></name><name><surname>Benediktsson</surname><given-names>R</given-names></name><name><surname>Manolescu</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.</article-title><source>Nat Genet</source><volume>38</volume><fpage>320</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">16415884</pub-id></mixed-citation></ref><ref id="pone.0007231-Scott1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Sprau</surname><given-names>AG</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><etal/></person-group><year>2006</year><article-title>Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample.</article-title><source>Diabetes</source><volume>55</volume><fpage>2649</fpage><lpage>2653</lpage><pub-id pub-id-type="pmid">16936217</pub-id></mixed-citation></ref><ref id="pone.0007231-Saxena1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>R</given-names></name><name><surname>Gianniny</surname><given-names>L</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Giuducci</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals.</article-title><source>Diabetes</source><volume>55</volume><fpage>2890</fpage><lpage>2895</lpage><pub-id pub-id-type="pmid">17003358</pub-id></mixed-citation></ref><ref id="pone.0007231-Groves1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groves</surname><given-names>CJ</given-names></name><name><surname>Zeggini</surname><given-names>E</given-names></name><name><surname>Minton</surname><given-names>J</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><etal/></person-group><year>2006</year><article-title>Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk.</article-title><source>Diabetes</source><volume>55</volume><fpage>2640</fpage><lpage>2644</lpage><pub-id pub-id-type="pmid">16936215</pub-id></mixed-citation></ref><ref id="pone.0007231-Reya1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year>2005</year><article-title>Wnt signalling in stem cells and cancer.</article-title><source>Nature</source><volume>434</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">15829953</pub-id></mixed-citation></ref><ref id="pone.0007231-He1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name><name><surname>Zawel</surname><given-names>L</given-names></name><etal/></person-group><year>1998</year><article-title>Identification of c-MYC as a target of the APC pathway.</article-title><source>Science</source><volume>281</volume><fpage>1509</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">9727977</pub-id></mixed-citation></ref><ref id="pone.0007231-Muncan1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muncan</surname><given-names>V</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Tertoolen</surname><given-names>L</given-names></name><name><surname>Phesse</surname><given-names>TJ</given-names></name><name><surname>Begthel</surname><given-names>H</given-names></name><etal/></person-group><year>2006</year><article-title>Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc.</article-title><source>Mol Cell Biol</source><volume>26</volume><fpage>8418</fpage><lpage>8426</lpage><pub-id pub-id-type="pmid">16954380</pub-id></mixed-citation></ref><ref id="pone.0007231-Tetsu1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetsu</surname><given-names>O</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year>1999</year><article-title>Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.</article-title><source>Nature</source><volume>398</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">10201372</pub-id></mixed-citation></ref><ref id="pone.0007231-Merrill1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>BJ</given-names></name><name><surname>Gat</surname><given-names>U</given-names></name><name><surname>DasGupta</surname><given-names>R</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group><year>2001</year><article-title>Tcf3 and Lef1 regulate lineage differentiation of multipotent stem cells in skin.</article-title><source>Genes Dev</source><volume>15</volume><fpage>1688</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">11445543</pub-id></mixed-citation></ref><ref id="pone.0007231-Ross1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>SE</given-names></name><name><surname>Hemati</surname><given-names>N</given-names></name><name><surname>Longo</surname><given-names>KA</given-names></name><name><surname>Bennett</surname><given-names>CN</given-names></name><name><surname>Lucas</surname><given-names>PC</given-names></name><etal/></person-group><year>2000</year><article-title>Inhibition of adipogenesis by Wnt signaling.</article-title><source>Science</source><volume>289</volume><fpage>950</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">10937998</pub-id></mixed-citation></ref><ref id="pone.0007231-Miranda1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>PJ</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Guyton</surname><given-names>JR</given-names></name></person-group><year>2005</year><article-title>Metabolic syndrome: definition, pathophysiology, and mechanisms.</article-title><source>Am Heart J</source><volume>149</volume><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15660032</pub-id></mixed-citation></ref><ref id="pone.0007231-Florez1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Bayley</surname><given-names>N</given-names></name><name><surname>Pollin</surname><given-names>TI</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name><etal/></person-group><year>2006</year><article-title>TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.</article-title><source>N Engl J Med</source><volume>355</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">16855264</pub-id></mixed-citation></ref><ref id="pone.0007231-Cauchi1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauchi</surname><given-names>S</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Choquet</surname><given-names>H</given-names></name><name><surname>Samson</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes.</article-title><source>Diabetes</source><volume>55</volume><fpage>2903</fpage><lpage>2908</lpage><pub-id pub-id-type="pmid">17003360</pub-id></mixed-citation></ref><ref id="pone.0007231-Cauchi2"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauchi</surname><given-names>S</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Choquet</surname><given-names>H</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Born</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>TCF7L2 Variation Predicts Hyperglycemia Incidence in a French General Population: The Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) Study.</article-title><source>Diabetes</source><volume>55</volume><fpage>3189</fpage><lpage>3192</lpage><pub-id pub-id-type="pmid">17065361</pub-id></mixed-citation></ref><ref id="pone.0007231-Cauchi3"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauchi</surname><given-names>S</given-names></name><name><surname>Choquet</surname><given-names>H</given-names></name><name><surname>Gutierrez-Aguilar</surname><given-names>R</given-names></name><name><surname>Capel</surname><given-names>F</given-names></name><name><surname>Grau</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Effects of TCF7L2 polymorphisms on obesity in European populations.</article-title><source>Obesity (Silver Spring)</source><volume>16</volume><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">18239663</pub-id></mixed-citation></ref><ref id="pone.0007231-Zhang1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>S</given-names></name><name><surname>Bleibel</surname><given-names>WK</given-names></name><name><surname>Wisel</surname><given-names>SA</given-names></name><name><surname>Huang</surname><given-names>RS</given-names></name><etal/></person-group><year>2008</year><article-title>Identification of common genetic variants that account for transcript isoform variation between human populations.</article-title><source>Hum Genet</source></mixed-citation></ref><ref id="pone.0007231-Graham1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>Kozyrev</surname><given-names>SV</given-names></name><name><surname>Baechler</surname><given-names>EC</given-names></name><name><surname>Reddy</surname><given-names>MV</given-names></name><name><surname>Plenge</surname><given-names>RM</given-names></name><etal/></person-group><year>2006</year><article-title>A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.</article-title><source>Nat Genet</source><volume>38</volume><fpage>550</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">16642019</pub-id></mixed-citation></ref><ref id="pone.0007231-Elbein1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbein</surname><given-names>SC</given-names></name><name><surname>Chu</surname><given-names>WS</given-names></name><name><surname>Das</surname><given-names>SK</given-names></name><name><surname>Yao-Borengasser</surname><given-names>A</given-names></name><name><surname>Hasstedt</surname><given-names>SJ</given-names></name><etal/></person-group><year>2007</year><article-title>Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent.</article-title><source>Diabetologia</source><volume>50</volume><fpage>1621</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">17579832</pub-id></mixed-citation></ref><ref id="pone.0007231-Lyssenko1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Lupi</surname><given-names>R</given-names></name><name><surname>Marchetti</surname><given-names>P</given-names></name><name><surname>Del Guerra</surname><given-names>S</given-names></name><name><surname>Orho-Melander</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.</article-title><source>J Clin Invest</source><volume>117</volume><fpage>2155</fpage><lpage>2163</lpage><pub-id pub-id-type="pmid">17671651</pub-id></mixed-citation></ref><ref id="pone.0007231-Osmark1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osmark</surname><given-names>P</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Jonsson</surname><given-names>A</given-names></name><name><surname>Ronn</surname><given-names>T</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><etal/></person-group><year>2009</year><article-title>Unique splicing pattern of the TCF7L2 gene in human pancreatic islets.</article-title><source>Diabetologia</source></mixed-citation></ref><ref id="pone.0007231-ProkuninaOlsson1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prokunina-Olsson</surname><given-names>L</given-names></name><name><surname>Welch</surname><given-names>C</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Adhikari</surname><given-names>N</given-names></name><name><surname>Scott</surname><given-names>L</given-names></name><etal/></person-group><year>2009</year><article-title>Tissue-specific alternative splicing of TCF7L2.</article-title><source>Hum Mol Genet</source></mixed-citation></ref><ref id="pone.0007231-httphapmap.org1"><label>22</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="http://hapmap.org/">http://hapmap.org/</ext-link></mixed-citation></ref><ref id="pone.0007231-Zhong1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Beaulaurier</surname><given-names>J</given-names></name><name><surname>Lum</surname><given-names>PY</given-names></name><name><surname>Molony</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><year>2009</year><article-title>Elucidating Networks of eSNPs Associated with Type 2 Diabetes.</article-title><source>PLOS Biology</source><comment>in press</comment></mixed-citation></ref><ref id="pone.0007231-Wegner1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wegner</surname><given-names>L</given-names></name><name><surname>Hussain</surname><given-names>MS</given-names></name><name><surname>Pilgaard</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name><etal/></person-group><year>2008</year><article-title>Impact of TCF7L2 rs7903146 on Insulin Secretion and Action in Young and Elderly Danish Twins.</article-title><source>J Clin Endocrinol Metab</source></mixed-citation></ref><ref id="pone.0007231-Kovacs1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>P</given-names></name><name><surname>Berndt</surname><given-names>J</given-names></name><name><surname>Ruschke</surname><given-names>K</given-names></name><name><surname>Kloting</surname><given-names>N</given-names></name><name><surname>Schon</surname><given-names>MR</given-names></name><etal/></person-group><year>2008</year><article-title>TCF7L2 gene expression in human visceral and subcutaneous adipose tissue is differentially regulated but not associated with type 2 diabetes mellitus.</article-title><source>Metabolism</source><volume>57</volume><fpage>1227</fpage><lpage>1231</lpage><pub-id pub-id-type="pmid">18702948</pub-id></mixed-citation></ref><ref id="pone.0007231-Fang1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Blauwkamp</surname><given-names>T</given-names></name><name><surname>Bhambhani</surname><given-names>C</given-names></name><name><surname>Campbell</surname><given-names>N</given-names></name><etal/></person-group><year>2006</year><article-title>C-terminal-binding protein directly activates and represses Wnt transcriptional targets in Drosophila.</article-title><source>EMBO J</source><volume>25</volume><fpage>2735</fpage><lpage>2745</lpage><pub-id pub-id-type="pmid">16710294</pub-id></mixed-citation></ref><ref id="pone.0007231-Thomas1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>PD</given-names></name><name><surname>Kejariwal</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>N</given-names></name><name><surname>Mi</surname><given-names>H</given-names></name><name><surname>Campbell</surname><given-names>MJ</given-names></name><etal/></person-group><year>2006</year><article-title>Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools.</article-title><source>Nucleic Acids Res</source><volume>34</volume><fpage>W645</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">16912992</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was supported by the Intramural Research Programs of the NHGRI and NCI/NIH. One of the authors (EES) is employed by Pacific Biosciences. The company did not have a role in funding or oversight of this study, data collection and analysis, decision to publish, or preparation of the manuscript. No patent can be claimed based on this study.</p></fn></fn-group></back></article>